Physician profile
Robert Carlson
NPI 1396856910
$7,968.70
in general payments reported to CMS, 2019-2025
50 companies · $801 in 2025
The $801 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $988 · 2021: $1,734 · 2022: $1,357 · 2023: $1,198 · 2024: $973 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,105.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $728.62 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $667.28 | 2019-2025 | Veozah |
| Novo Nordisk INC | $595.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.14 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $562.99 | 2019-2025 | |
| Lilly USA, LLC | $376.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $335.05 | 2019-2025 | Repatha, Otezla, Evenity |
| Teva Pharmaceuticals USA, INC. | $255.17 | 2022-2025 | Austedo Xr, Austedo, Ajovy |
| Amarin Pharma, INC. | $239.24 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.32 | 2021-2024 | |
| Glaxosmithkline, LLC. | $228.93 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Watermark Medical, INC. | $201.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $182.05 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $178.00 | 2019-2023 | Livalo, Seglentis |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.